Table 1 Representative targets within the lipid metabolism pathway for anti-cancer drug development
From: Lipid metabolism reprogramming and its potential targets in cancer
| Target protein | Inhibitor | Type of cancer | Preclinical model | Clinical trial | References |
|---|---|---|---|---|---|
| SCAP | – | GBM | Xenografts | – | [55] |
| SREBPs | Fatostatin, betulin, PF-429242, xanthohumol | GBM, prostate, liver, skin, melanoma, colorectal, bile duct, pancreatic, and breast cancer | Xenografts | – | [28, 125,126,127,128,129,130,131,132,133,134,135,136,137,138] |
| ACCs | TOFA, soraphen A, ND-646 | Lung, ovarian cancer, head and neck squamous cell carcinoma | Xenografts | – | [179,180,181,182,183,184,185] |
| ACLY | SB-204990, bempedoic acid, BMS303141 | Lung, prostate, and ovarian cancer | Xenografts | – | [152, 162, 165] |
| FASN | Cerulenin | Ovarian cancer, breast cancer | Xenografts | – | [179, 194,195,196] |
| C75 | Breast, GBM, renal, and mesothelioma cancer | Xenografts | – | [34, 179, 188, 197,198,199,200,201,202,203] | |
| TVB-2640 | Solid malignant tumors | – | Phase I | Clinicaltrials.gov (NCT02223247), [191] | |
| TVB-3166 | Lung, ovary, and pancreatic cancer | Xenografts | – | [264] | |
| C93 | Ovarian and lung cancer | Xenografts | – | [265, 266] | |
| C247 | Breast cancer | – | [267] | ||
| Orlistat | Prostate cancer and melanoma | Xenografts | – | [192, 193] | |
| Triclosan | Breast cancer | Xenografts | – | [268, 269] | |
| LDLR | – | GBM | – | – | [27, 219] |
| SCD1 | BZ36, A939572, MF-438 | Prostate, renal cancer | Xenografts | – | [124, 212,213,214,215, 270] |
| LXR | GW3965, LXR-623 | GBM | Xenografts | – | [27, 238, 239] |
| SR9243 | Prostate cancer | Xenografts | [242] | ||
| SOAT1 (or ACAT1) | K604, ATR-101, avasimibe | GBM, prostate and pancreatic cancer | Xenografts | – | [28, 230,231,232] |
| CPT1 | Etomoxir, perhexiline | Leukemia, prostate and breast cancer | Xenografts, transgenic mice | – | [248,249,250, 271, 272] |
| CD36 | Anti-CD36 antibodies | Oral cancer | Xenografts | – | [24,25,26] |